The global Veterinary Diagnostics Market, valued at US$3.42 billion in 2024 and standing at US$3.68 billion in 2025, is projected to advance at a resilient compound annual growth rate (CAGR) of 7.8% from 2025 to 2030, culminating in a forecasted valuation of US$5.36 billion by the end of the period. The market is expanding rapidly, driven by significant technological advancements such as point-of-care testing devices, molecular diagnostics (like PCR and LAMP), and AI-driven analysis tools, which are making diagnostics more accurate, faster, and accessible. Diagnostics for diabetes, kidney disorders, and infectious diseases—especially in companion animals—are rising rapidly. The increased prevalence of zoonotic diseases and infections transmitted between animals and humans significantly contributes to market growth.\n\nBy animal type, the market is segmented into companion animals and livestock. The companion animals segment accounted for the largest share in 2024, attributed to the rising number of households owning pets such as dogs and cats. The growing companion animal population, combined with increasing pet health awareness and the rising ability of pet owners to spend on healthcare, is fueling demand for advanced diagnostic tests and treatment options.\n\nBy end users, the market is segmented into veterinary reference laboratories, veterinary hospitals & clinics, POC/in-house testing, and veterinary research institutes & universities. The POC/In-house testing segment is expected to grow at the highest CAGR during the forecast period. POC testing is designed for use in livestock farms outside the physical facilities of clinical laboratories. The demand for improved patient care and greater cost control is driving changes in animal healthcare delivery, increasing the need for POC diagnostic testing. Technological advancements are enabling more diagnostic tests to move from clinical laboratories to the near-patient environment.\n\nBy geography, the market is segmented into North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. The Asia Pacific region is estimated to be the fastest-growing region due to rapid urbanization, growing pet adoption, and increasing awareness about animal health. Rising disposable incomes in countries like China and India are expected to lead to higher spending on companion animal care. Governments in the region are strengthening livestock disease surveillance and control programs to ensure food safety and prevent zoonotic outbreaks. Expanding veterinary infrastructure, increasing penetration of multinational diagnostic companies, and growing investments in animal health R&D are accelerating market growth.\n\nKey players in the market include IDEXX Laboratories, Inc. (US), Zoetis Services LLC (US), Thermo Fisher Scientific Inc. (US), Antech Diagnostics, Inc. (US), and bioMérieux (France).\n\nIDEXX Laboratories, Inc. is a global leader in veterinary diagnostics and software, serving companion animal practices, livestock, and poultry markets. Its product line includes in-clinic analyzers such as Catalyst One (chemistry), ProCyte Dx (hematology), SNAP tests (rapid immunoassays), and the VETLAB Station for integrated diagnostics. In 2023, IDEXX launched Cystatin B, a novel biomarker test for early kidney injury detection in cats and dogs. The company continues to enhance its cloud-based VetConnect PLUS platform, enabling real-time diagnostic results, analytics, and AI-driven insights. The Vetscan Imagyst, powered by AI, supports cytology, fecal, and dermatology diagnostics. IDEXX invests heavily in R&D, allocating over 6% of annual revenue to innovation focused on expanding diagnostic precision and integrating digital workflows for faster decision-making.\n\nZoetis Services LLC operates one of the broadest portfolios in veterinary diagnostics, catering to both companion animals and livestock. Its diagnostics business includes point-of-care instruments such as the VETSCAN series, VETSCAN VS2, VETSCAN Imagyst, and VETSCAN SA for hematology, chemistry, and AI-assisted slide analysis. In 2024, Zoetis launched the VETSCAN OptiCell, an AI-powered, cartridge-based hematology analyzer that delivers CBC results in under 5 minutes. The company is advancing R&D in molecular and biomarker-based tests, including expanding the capabilities of its Imagyst platform to support microbiology and oncology diagnostics. In January 2024, it added an AI Urine sediment analysis program to its Imagyst platform. In June 2025, Zoetis launched AI Masses, an AI-powered analysis technology to be integrated into the Vetscan Imagyst analyzer. The company invests significantly in AI and digital innovation to streamline veterinary workflows and improve diagnostic speed and accuracy across species.\n\nThermo Fisher Scientific's veterinary diagnostics portfolio is anchored in molecular diagnostics, ELISA kits, and PCR-based tests, primarily serving the livestock and research animal sectors. It also supports companion animal diagnostics. Its VetMAX product line provides real-time PCR solutions for detecting diseases such as avian influenza, bovine viral diarrhea (BVD), and African swine fever. Thermo Fisher is known for its high-throughput and precise qPCR platforms like QuantStudio and Applied Biosystems instruments used in veterinary labs. The company invests heavily in R&D to develop custom assay kits and improve sample-to-answer turnaround times, focusing on zoonotic disease monitoring and biosecurity diagnostics. Collaborations with government and food safety agencies have expanded its global animal health surveillance role.

Veterinary Diagnostics Market worth US$5.36 billion by 2030 with 7.8% CAGR | MarketsandMarkets™

The global Veterinary Diagnostics Market is projected to grow from US$3.68 billion in 2025 to US$5.36 billion by 2030 at a compound annual growth rate (CAGR) of 7.8%, driven by technological advancements such as point-of-care testing, molecular diagnostics, and AI-driven analysis. Demand is rising for diagnostics in companion animals, particularly for diabetes, kidney disorders, and infectious diseases, with zoonotic disease concerns accelerating market expansion. The companion animals segment dominates the market, fueled by rising pet ownership and increased pet healthcare spending. The POC/in-house testing segment is expected to grow at the highest CAGR due to demand for cost-effective, near-patient testing. The Asia Pacific region is the fastest-growing geographically, due to urbanization, rising pet adoption, and government initiatives in animal health and food safety. Key players include IDEXX Laboratories, Zoetis Services LLC, Thermo Fisher Scientific, Antech Diagnostics, and bioMérieux.